Articles by Sean Milmo - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Sean Milmo

EMA Collaborates with HTA Assessment Networks

High technology assessments are having an impact on biosimilars development in Europe.
Feb 2, 2014

High technology assessments are having an impact on biosimilars development in Europe.

Early Communication with Regulators is Essential for SMEs

With SMEs gaining wider recognition as the powerhouse of research and innovation in Europe, regulatory agencies are urging companies to engage with regulators early in the drug-development process.
Jan 2, 2014

With SMEs gaining wider recognition as the powerhouse of research and innovation in Europe, regulatory agencies are urging companies to engage with regulators early in the drug-development process.

Regulation of Biosimilars: A Matter of Variability, Similarity, and Comparability

As the European Union takes a closer look at its biosimilars guidelines, some key issues are proving difficult to resolve.
Dec 2, 2013

The European Union is strengthening its pioneering role in the regulation of biosimilars by further developing the basic rules for determining the levels of compatibility for this group of drugs. There are, however, some key issues that are not easy to resolve, as evident in a recent workshop on biosimilars organized by the European Medicines Agency (EMA).

European Union Introduces GMPs for Excipients

Regulators hope new standards will stop illegal drug imports, but manufacturers fear they may stifle innovation.
Nov 2, 2013

Regulators hope new standards will stop illegal drug imports, but manufacturers fear they may stifle innovation.

EU Raises API Standards: A Curse in Disguise?

The aim of the European Falsified Medicines Directive is to improve the quality of imported APIs, but does the pain now outweigh the gain?
Sep 2, 2013

The aim of the European Falsified Medicines Directive is to improve the quality of imported APIs, but does the pain now outweigh the gain?

Seeking Harmonization in Nanomedicines Regulatory Framework

Nanomedicines have been authorized by European licensing agencies for more than 30 years but are still posing regulatory difficulties.
Aug 2, 2013

Nanomedicines have been authorized by European licensing agencies for more than 30 years but are still posing regulatory difficulties.

EU Battles Medicine Shortages

European governments are under pressure to take regulatory action, but solving the problem of medicine shortages is not as straightforward as it seems.
Jul 2, 2013

European governments are under pressure to take regulatory action, but solving the problem of medicine shortages is not as straightforward as it seems.

A Lifecycle Approach to Process Validation

A science- and risk-based approach to verify and demonstrate that a process operating within predefined specified parameters consistently produces material that meets all its critical quality attributes.
Jun 2, 2013

A science- and risk-based approach to verify and demonstrate that a process operating within predefined specified parameters consistently produces material that meets all its critical quality attributes.

Should Regulation of Combination Products Become More Centralized in Europe?

While there are those who want combination products to be controlled by a centralized pharmaceutical-type approval system, the majority of the medical technology industry wants to retain a decentralized device-focused approach.
May 2, 2013

While there are those who want combination products to be controlled by a centralized pharmaceutical-type approval system, the majority of the medical technology industry wants to retain a decentralized device-focused approach.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here